WANBURY240.65

Wanbury Limited

· Pharma & Health
₹ CrorePeersAHCLANUHPHRBAJAJHCARETHEMISMEDZIMLABLINCOLNSIGACHIVALIANTLABMcap ₹789 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Last 12M
30/06/2025
Returns
Return on Common Equity31.68200.2651.5151.51
Return on Assets-3.4216.297.387.38
Return on Capital Employed-65.3644.0326.3326.33
Return on Invested Capital36.1742.0727.6032.57
Margins
EBITDA Margin4.6412.1612.7313.98
Operating Margin2.169.9010.5110.51
Incremental Operating Margin60.7725.30
Pretax Margin-2.069.794.936.69
Net Income Margin-2.089.725.096.82
FCF Margin3.96-2.34-3.82-3.82
Additional
Effective Tax Rate-1.060.68-3.31-2.05
Sustainable Growth Rate31.68200.2651.5151.51
Incremental Operating Margin %60.7725.3037.44
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.